Results 181 to 190 of about 37,077 (282)

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. [PDF]

Cancer Chemother Pharmacol
Ji X, Yang Y, Ma C, Huang W, Guo S, Wang L, Zheng H, Wu X.   +7 more
europepmc   +1 more source

NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells. [PDF]

Oncoimmunology
Heger L, Kaszubowski T, Amon L, Lehmann CHK, Wingert S, Medina-Echeverz J, Koch J, Hackstein H, Purbojo A, Hartmann A, Alexiou C, Cesnjevar R, Pahl J, Dudziak D.   +13 more
europepmc   +1 more source

Bispecific Antibody MDX447 [PDF]

, 2020
openaire   +1 more source

Non‐Operable Squamous Cell Carcinoma of the Infraorbital Region Treated With Electrochemotherapy: A Case Report

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Cutaneous squamous cell carcinoma (cSCC) is a malignant epithelial tumor of the skin, classified as a nonmelanoma skin cancer. It may develop from precancerous conditions such as chronic inflammatory dermatoses, actinic keratosis, or actinic cheilitis, but can also arise de novo.
Gianluca Nicolai, Francesco Campanella, Sergio Alexandre Gehrke, Antonio Scarano   +3 more
wiley   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition. [PDF]

Front Immunol
Zhu X, Cui X, Yu H, Xu J, Chen X, Ren X, Wei X, Chen S, Wang Y, Fei L, Xie B, Li M, Li X, Jia H, Feng Y, Xia S, Chen L, Cheng Y, Zhang L, Li H, Zhu X, Zhan Y.   +21 more
europepmc   +1 more source

Process Systems Engineering in Precision Medicine: Opportunities in Autologous CAR‐T Therapy

Engineering in Life Sciences, Volume 26, Issue 2, February 2026.
ABSTRACT Autologous chimeric antigen receptor (CAR)‐T therapies have given hope to many cancer patients whose other lines of treatment have failed. Unfortunately, limited manufacturing capability has resulted in many patients dying while on a waitlist.
B. Wayne Bequette
wiley   +1 more source

Bispecific Antibody 4G7xH22 [PDF]

, 2020
openaire   +1 more source

Integrative Omics Analysis Reveals the Potential Value of CEACAM6 in Pan‐Gastrointestinal Cancers

Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
Expression of CEACAM6 in spatial transcriptomic of colorectal cancer with liver metastases. (A) Predicted cell types mapping on colorectal cancer tissue slice; (B) Spatial distribution of CEACAM6; (C) Spatial distribution of malignant region, mixed region and normal region; (D) The difference expression of CEACAM6 in malignant region, mixed region and ...
Liying Jin, Changjuan Tao, Zhiyong Pan, Peng Zhang   +3 more
wiley   +1 more source

Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives. [PDF]

Front Immunol
Lopatnikova JA, Sennikov SV.
europepmc   +1 more source